Ferring v. Jiangsu Hansoh: Six Degarelix Patents, 734-Day Delaware Dispute
Ferring Pharmaceuticals and three affiliates sued Chinese generics group Jiangsu Hansoh in Delaware over six patents covering degarelix manufacture and GnRH antagonist-based prostate cancer treatment. The parties reached a private settlement after 734 days, dismissing all claims without prejudice — leaving enforcement optionality intact for Ferring.
Ferring’s Six-Patent Degarelix Enforcement Ends in Private Settlement
Filed in November 2022, this infringement action before Judge Maryellen Noreika in the District of Delaware saw Ferring Pharmaceuticals, Inc., Ferring International Center S.A., Ferring B.V., and Polypeptide Laboratories A/S collectively assert six US patents against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. The patents — US9579359B2, US9415085B2, US10729739B2, US10695398B2, US10973870B2, and US8828938B2 — cover methods for manufacturing degarelix and treating prostate cancer with GnRH antagonists, the pharmacological class to which degarelix belongs.
After 734 days of litigation, the parties filed a stipulated voluntary dismissal in November 2024, citing a private settlement agreement. The dismissal was entered without prejudice under FRCP 41(a)(1)(A)(ii), meaning the Court retains jurisdiction to enforce the settlement agreement but Ferring technically retains the right to refile if the settlement terms are breached. Each party was ordered to bear its own attorneys’ fees and costs, a neutral cost outcome consistent with a negotiated resolution rather than a decisive win for either side.
A 734-day lifespan without a published merits ruling suggests the case progressed through at least early discovery or claim construction before the parties found common ground. The without-prejudice dismissal is commercially significant: it preserves Ferring’s enforcement leverage if Hansoh’s conduct under any licensing or market-access terms diverges from the agreement. The financial terms of the settlement, any licensing arrangement, and any agreed market-entry timeline for Hansoh’s degarelix product remain undisclosed in the public record.
Filing to Voluntary dismissal in 734 days
734 days — above the median for settled pharma patent disputes in Delaware District Court
Voluntarily dismissed: what the without-prejudice stipulation means for both parties
FRCP 41(a)(1)(A)(ii): stipulated dismissal by agreement
A Rule 41(a)(1)(A)(ii) dismissal requires both parties’ consent and is typically used to close litigation once a settlement is reached. The court formally exits the dispute but retains jurisdiction to enforce the underlying settlement agreement. No merits determination was made — no patent was held valid, invalid, infringed, or not infringed by any judicial ruling.
No merits adjudicationWithout prejudice: the public record is silent on the distinction’s practical effect
The dismissal was entered expressly without prejudice, meaning Ferring is not barred from refiling claims on these patents if settlement terms are breached. With-prejudice dismissals extinguish the right to refile; without-prejudice dismissals preserve it. The settlement agreement itself — which may contain standstill, licensing, or non-suit provisions — is not public, so the real-world enforceability posture depends on undisclosed contractual terms.
Refiling right preservedEnforcement leverage retained through private settlement
For Ferring, the without-prejudice structure and court-retained jurisdiction create a dual enforcement mechanism: the settlement agreement itself is enforceable by motion, and the underlying patent claims remain live if the agreement collapses. This outcome is consistent with brand-side strategy in Hatch-Waxman-adjacent pharmaceutical disputes, where controlling market timing is often more valuable than a courtroom win.
Dual enforcement pathMarket access likely governed by undisclosed settlement terms
For Jiangsu Hansoh, the absence of a with-prejudice dismissal means the patent cloud over its degarelix product is not judicially lifted — validity and non-infringement were never adjudicated. Its commercial freedom depends entirely on what the private settlement permits. Competitors in the GnRH antagonist space cannot rely on this outcome as precedent and should conduct independent FTO analysis against Ferring’s six asserted patents.
No patent cloud liftedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ferring Pharmaceuticals, Inc. | Company | Global biopharmaceutical group — holders of six degarelix manufacture and GnRH antagonist treatment patentsSearch in Eureka ↗ |
| Co-Plaintiff | Ferring International Center S.A. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Polypeptide Laboratories, AS | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Ferring B.V. | Individual | Search in Eureka ↗ |
| Defendant | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Company | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. — major Chinese pharma group seeking degarelix market entrySearch in Eureka ↗ |
| Plaintiff counsel | Ben Bourke | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dana Kathryn Severance | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joshua P. Davis | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kimberlynn R. Seifert | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mary W. Bourke | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Womble Bond Dickinson (US) LLP | Law Firm | Representing Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Taylor | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Elizabeth M. Crompton | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Eve H. Ormerod | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | H. Howard Wang | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Jason A. Lief | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Kyle C. Musgrove | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Neal C. Belgam | Attorney | Counsel for Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel LLP | Law Firm | Representing Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Smith, Katzenstein, & Jenkins LLP | Law Firm | Representing Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal order reflects a fully negotiated exit: all claims, counterclaims, and affirmative defenses — including any invalidity or non-infringement defenses Hansoh raised — are dismissed simultaneously. The court’s retained jurisdiction clause is the operative enforcement lever. The mutual cost-bearing provision is consistent with settlement parity and does not signal relative bargaining strength. No merits finding was made on any of the six patents, leaving their validity and enforceability entirely intact as a matter of public patent law.
US9579359B2 — Degarelix Manufacture and GnRH Antagonist Treatment Methods
The six asserted patents — US9579359B2, US9415085B2, US10729739B2, US10695398B2, US10973870B2, and US8828938B2 — span manufacturing process claims for degarelix, a synthetic decapeptide GnRH antagonist, and method-of-treatment claims for prostate cancer. Application dates across the family range from the early 2010s through to 2020, suggesting Ferring has systematically extended its IP coverage as degarelix manufacturing processes matured and clinical use expanded. Polypeptide Laboratories A/S, a contract manufacturer co-plaintiff, indicates the manufacturing chain itself is within the scope of asserted rights.
Degarelix (marketed as Firmagon) is a high-value oncology agent with no generic equivalent at scale in Western markets. The inclusion of method-of-manufacture claims alongside treatment method claims creates a broad enforcement perimeter: a generic or biosimilar entrant must design around both the synthesis process and the clinical use protocol. For companies in the GnRH antagonist space — including those developing relugolix or other alternatives — Ferring’s patent cluster represents a precedent for aggressive portfolio-based enforcement against any perceived encroachment on degarelix market share.
Should you run an FTO against Ferring’s degarelix patent portfolio?
Any company developing, manufacturing, or commercialising degarelix or a closely related GnRH antagonist peptide in the US market should treat Ferring’s six-patent cluster as a live enforcement risk. The Hansoh settlement does not establish non-infringement — it resolves one dispute privately. ANDA filers, contract peptide manufacturers, and oncology biosimilar developers should commission FTO analysis covering all six asserted patents before committing to manufacturing scale-up or US regulatory filings.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope across Ferring’s degarelix and GnRH antagonist portfolio in minutes, identify design-around opportunities in synthesis or formulation, and benchmark against cited prior art. Eureka’s litigation monitoring module also tracks any new enforcement actions Ferring files against degarelix competitors, providing early warning before litigation reaches your organisation.
Run a freedom-to-operate analysis on US9579359B2 to assess your product’s exposure
Run FTO in Eureka →Similar Pharmaceutical GnRH Antagonist Patent Cases in Delaware District Court
Cases involving peptide pharmaceutical patent enforcement and GnRH antagonist method claims in Delaware District Court, resolved by settlement or voluntary dismissal.
What this case signals for the GnRH antagonist and degarelix IP landscape
Six-patent enforcement by a brand incumbent against a Chinese generics entrant, resolved privately — a pattern with direct implications for degarelix biosimilar and generic strategies.
Without-prejudice dismissals preserve brand-side leverage in pharma patent disputes
Ferring’s use of a without-prejudice structure is a deliberate enforcement tool. Any competitor or generics group planning degarelix market entry should assume Ferring’s patent portfolio remains fully enforceable and that the Hansoh settlement does not create a free-ride precedent. Independent FTO analysis against all six asserted patents is essential before any commercial step.
Six-patent clusters signal deep defensive IP strategy around degarelix
Asserting six patents covering both manufacturing methods and treatment methods in a single action signals that Ferring has constructed layered IP protection around degarelix. Challengers face both composition-of-matter and method claim exposure. Any ANDA or biosimilar filer targeting this molecule should expect multi-patent litigation rather than a single-front dispute.
Ferring v Jiangsu — key questions answered
Ferring asserted six patents: US9579359B2, US9415085B2, US10729739B2, US10695398B2, US10973870B2, and US8828938B2. All relate to methods for manufacturing degarelix or treating prostate cancer using GnRH antagonists. The case was filed in November 2022 in the District of Delaware and settled in November 2024.
A voluntary dismissal without prejudice under FRCP 41(a)(1)(A)(ii) means Ferring’s claims were not resolved on the merits. Ferring retains the legal right to refile claims against Hansoh if the settlement agreement is breached. The six asserted patents remain valid and enforceable as a matter of public record — no invalidity finding was made.
No merits determination was made in case 1:22-cv-01474. The case was resolved by mutual settlement and voluntarily dismissed without prejudice. This is not a win for Hansoh on validity or non-infringement grounds — the outcome simply reflects the parties reaching a private agreement whose terms are not publicly disclosed.
Degarelix is a synthetic GnRH antagonist peptide used to treat advanced prostate cancer by rapidly suppressing testosterone. Marketed as Firmagon by Ferring, it commands significant oncology market value. Its complex peptide synthesis and specialised dosing methods are covered by multiple patents, making it a target for both generics enforcement and brand-side litigation when competitors seek US market entry.
Polypeptide Laboratories A/S is a contract peptide manufacturer and co-owner of at least some of the asserted patents. Its inclusion as a plaintiff extends the infringement claim to cover manufacturing-level activities, not just downstream commercialisation. This signals that Ferring’s patent strategy encompasses the entire supply chain for degarelix, making it harder for a generic entrant to isolate a non-infringing manufacturing route.
PatSnap Eureka searches patents and litigation data to answer instantly.